WAINUA (AstraZeneca Pty Ltd)
Product name
WAINUA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
171 (255 working days)
Active ingredients
eplontersen sodium
Registration type
NCE/NBE
Indication
WAINUA is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.